Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Dyslipidemia

Dyslipidemia

16 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Dyslipidemia

72 trials tracked for Dyslipidemia: 33 in phase 3 or 4 and 7 with published results. The most-cited published study has 481 citations.

72Trials tracked
33Phase 3 & 4
0Recruiting
7With published results
Phase distribution
Phase 4 7 Phase 3 26 Phase 2 15 Phase 1 6 Other / NA 18
  1. Phase 3 Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects Completed · 481 cited
  2. Phase 3 Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension Completed · 378 cited
  3. Phase 3 Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Completed · 169 cited
  4. Phase 4 Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia) Completed · 126 cited
  5. Phase 4 Effects of Metformin on Hepatic FFA Metabolism Completed · 63 cited
  6. Phase 4 Effects of Pitavastatin on Lipid Profiles in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir Completed · 11 cited
Show 44 more trials
  1. Phase 3 Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia Completed · 7 cited
  2. Phase 4 Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients Completed
  3. Phase 4 A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects Completed
  4. Phase 4 A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk Completed
  5. Phase 4 Effect of Plant Sterols Esterified to Fish Oil Fatty Acids on Plasma Lipid Levels Completed
  6. Phase 3 Fenofibrate Treatment in SCI Completed
  7. Phase 3 12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia Completed
  8. Phase 3 Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood Completed
  9. Phase 3 A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia Completed
  10. Phase 3 Follow-on Protocol of Pitavastatin Versus Simvastatin in Patients With Hypercholesterolemia or Dyslipidemia and Coronary Heart Disease Risk Factors Completed
  11. Phase 3 Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood Completed
  12. Phase 3 Study Comparing Pitavastatin and Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia Completed
  13. Phase 3 Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia. Completed
  14. Phase 3 A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease Completed
  15. Phase 3 Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin Completed
  16. Phase 3 30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease Completed
  17. Phase 3 Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin Completed
  18. Phase 3 A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia Completed
  19. Phase 3 Study to Compare the Efficacy of Pitavastatin With That of Atorvastatin in Lowering Cholesterol Levels Completed
  20. Phase 3 Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin Completed
  21. Phase 3 Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia Completed
  22. Phase 3 Multi-Targeted Cardiac Risk Intervention in Type 2 Diabetes Completed
  23. Phase 3 Follow-On Study of Pitavastatin Versus Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia Completed
  24. Phase 3 Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood Completed
  25. Phase 3 Long-Term Extension Study of Pitavastatin in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia Completed
  26. Phase 3 Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood Completed
  27. Phase 3 A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102) Completed
  28. Phase 2 Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study Completed
  29. Phase 2 ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study Completed
  30. Phase 2 A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides Completed
  31. Phase 2 A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia Completed
  32. Phase 2 A Study of AZD8233 in Participants With Dyslipidemia. Completed
  33. Phase 2 Preliminary Study of Safety and Efficacy of Policosanol Completed
  34. Phase 2 Clinical Trial of Zocor (Simvastatin) and Vytorin (Ezetimibe/Simvastatin) in Adolescents With Type 1 Diabetes Completed
  35. Phase 2 A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins Completed
  36. Phase 2 A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy. Completed
  37. Phase 2 A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C) Completed
  38. Phase 2 A Study to Evaluate MK1903 in Patients With Dyslipidemia (MK1903-004) Completed
  39. Phase 2 A Study of LY2484595 in Patients With High LDL-C or Low HDL-C Completed
  40. Phase 2 A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins Completed
  41. Phase 2 Study to Investigate the Efficacy and Pharmacokinetic Profile of K-877-ER Compared to K-877-IR Completed
  42. Phase 2 Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia Completed
  43. Phase 1 Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia Completed
  44. Phase 1 MK0524B Bioequivalence Study (0524B-070) Completed

Showing the 50 most-cited and recently-updated of 72 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Meta-analysis finds oral JAK inhibitors increase HDL and LDL cholesterol levels in patients from RCTs
Dermatology Meta-analysis
Meta-analysis finds oral JAK inhibitors increase HDL and LDL cholesterol levels in patients from RCTs Common arthritis and skin drugs linked to cholesterol changes, analysis finds
A systematic review and meta-analysis of 13 phase 2 and 3 RCTs involving 5,658 patients found treatment with oral JAK inhibitors (baricitini…
Common arthritis and skin drugs can raise both 'good' and 'bad' cholesterol levels, a review of nearly 4,000 patients shows.
Apr 4, 2026
Nutrition and health canteen intervention linked to weight reduction in middle-aged adults
Diabetes & Endocrinology RCT
Nutrition and health canteen intervention linked to weight reduction in middle-aged adults Nutrition-focused workplace canteen program linked to weight loss in middle-aged adults
A single-group before–after study of 97 middle-aged adults in China found a multifaceted nutrition and health canteen intervention was assoc…
A 12-week workplace canteen program in China helped middle-aged adults lose weight by offering diverse foods and reducing salt, sugar, and o…
Frontiers Apr 4, 2026
Meta-analysis finds water-only fasting decreases HDL, increases LDL and total cholesterol
Diabetes & Endocrinology Meta-analysis
Meta-analysis finds water-only fasting decreases HDL, increases LDL and total cholesterol Does water-only fasting help your cholesterol? A new review suggests it might not
A systematic review and meta-analysis of 32 human studies examined water-only fasting effects on blood lipids.
Water-only fasting may lower good cholesterol and raise bad cholesterol, according to a new review of 32 human studies.
Frontiers Apr 4, 2026
Atorvastatin evaluated for dyslipidemia in children with steroid-sensitive nephrotic syndrome
Nephrology Phase IV
Atorvastatin evaluated for dyslipidemia in children with steroid-sensitive nephrotic syndrome Can a common cholesterol drug protect children's hearts and kidneys from a hidden danger?
A quasi-experimental study of 100 children aged 8-18 years with steroid-sensitive nephrotic syndrome and dyslipidemia evaluated the effectiv…
A common cholesterol drug called atorvastatin may help children with kidney disease reach safer heart and blood fat levels when diet alone i…
CT.gov Mar 30, 2026

Questions about Dyslipidemia

Are there metabolic problems linked to having chronic insomnia while hospitalized?

Yes, chronic insomnia in hospitalized adults is linked to metabolic problems, including elevated fasting blood glucose and dyslipidemia.

Full answer →
What blood proteins might help predict disease progression in people with cardiometabolic conditions?

Proteins like GDF15, ADM, PCSK9, HS-CRP, and S100 proteins may help predict disease progression in people with cardiometabolic conditions.

Full answer →
Does working night shifts cause higher total cholesterol levels in male miners?

Yes, night shift work is linked to higher total cholesterol in male miners, even after accounting for sleep quality, age, and lifestyle factors.

Full answer →
Can high cholesterol levels make kidney disease worse for patients with IgA nephropathy?

Yes, high cholesterol levels can worsen kidney disease in IgA nephropathy patients, as dyslipidemia is linked to poorer renal survival and more severe kidney damage.

Full answer →